David G Hicks

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma
    D G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester New York 14642, USA
    Biotech Histochem 88:121-31. 2013
  2. doi request reprint HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 19:506-8. 2011
  3. doi request reprint Immunohistochemistry in the diagnostic evaluation of breast lesions
    David G Hicks
    University of Rochester Medical Center, Elmwood Avenue, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 19:501-5. 2011
  4. pmc TLE3 as a candidate biomarker of response to taxane therapy
    Swati A Kulkarni
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Breast Cancer Res 11:R17. 2009
  5. pmc The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
  6. ncbi request reprint Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
    Arch Pathol Lab Med 132:1008-15. 2008
  7. doi request reprint The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research
    D G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Biotech Histochem 87:14-7. 2012
  8. doi request reprint Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Natl Cancer Inst Monogr 2011:43-5. 2011
  9. pmc Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh,
    Arch Pathol Lab Med 138:241-56. 2014
  10. ncbi request reprint HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools
    David G Hicks
    Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Am J Clin Pathol 129:263-73. 2008

Collaborators

Detail Information

Publications42

  1. doi request reprint The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma
    D G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester New York 14642, USA
    Biotech Histochem 88:121-31. 2013
    ..We review highlights of the clinical rationale that underlies HER2 testing for both breast and gastric carcinomas, and describe some of the challenges associated with ensuring accurate test results...
  2. doi request reprint HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 19:506-8. 2011
    ....
  3. doi request reprint Immunohistochemistry in the diagnostic evaluation of breast lesions
    David G Hicks
    University of Rochester Medical Center, Elmwood Avenue, Rochester, NY 14642, USA
    Appl Immunohistochem Mol Morphol 19:501-5. 2011
    ..This article will briefly review some of the more common circumstances in which IHC has been shown to be useful in diagnostic breast pathology...
  4. pmc TLE3 as a candidate biomarker of response to taxane therapy
    Swati A Kulkarni
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Breast Cancer Res 11:R17. 2009
    ..The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified...
  5. pmc The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
    David G Hicks
    Clarient Inc, Aliso Veijo, California, USA
    BMC Cancer 10:108. 2010
    ..Furthermore, the small but established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of biomarkers that might help stratify patients...
  6. ncbi request reprint Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
    Arch Pathol Lab Med 132:1008-15. 2008
    ..In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups...
  7. doi request reprint The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research
    D G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Biotech Histochem 87:14-7. 2012
    ..Inaccurate results owing to compromised tissue quality can lead to false positive or false negative results with therapeutic consequences that can harm patients and affect their eventual outcome...
  8. doi request reprint Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling
    David G Hicks
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Natl Cancer Inst Monogr 2011:43-5. 2011
    ..The quality of archival tissue samples for future biomarker research will also benefit...
  9. pmc Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh,
    Arch Pathol Lab Med 138:241-56. 2014
    ....
  10. ncbi request reprint HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools
    David G Hicks
    Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Am J Clin Pathol 129:263-73. 2008
    ..Rigorous quality control and standardization of the testing process, from the handling of tissue samples to interpretation and reporting of results, are essential for achieving accurate and reproducible assay results...
  11. doi request reprint Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas
    Sharlin Johnykutty
    Department of Pathology and Laboratory Medicine, University of Rochester Medical School, Rochester, NY 14642, USA
    Mod Pathol 22:770-5. 2009
    ....
  12. doi request reprint A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer
    Ping Tang
    Department of Pathology, University of Rochester of Rochester Medical Center, New York, USA
    Cancer Invest 28:978-82. 2010
    ..926 (mitosis) -2.408 (PR) -1.061 (HER2) + 7.051 (luminal A) + 29.172 (luminal B) predicts RS with an R² of 0.65. In conclusion, PR negativity, luminal B subtype, tubal formation, and mitosis are strongly correlated with a higher RS...
  13. pmc Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
    Christopher T Ritchlin
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Clin Invest 111:821-31. 2003
    ..This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone...
  14. pmc HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma
    Yingchuan Hu
    Department of Pathology, University of Rochester, Rochester, NY, USA
    Mod Pathol 24:899-907. 2011
    ..A modified two-step model for esophageal adenocarcinoma HER2 testing is recommended for clinical esophageal adenocarcinoma HER2 trial...
  15. pmc Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)
    Ya Hui Chiu
    Allergy Immunology and Rheumatology Division, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA
    J Bone Miner Res 27:79-92. 2012
    ..Taken together, these data show that DC-STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC-STAMP dynamically regulates cell signaling during osteoclastogenesis...
  16. ncbi request reprint Expression of androgen receptor and its association with estrogen receptor and androgen receptor downstream proteins in normal/benign breast luminal epithelium
    Xi Wang
    Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY
    Appl Immunohistochem Mol Morphol 22:498-504. 2014
    ..Our study did not reveal the expression of AR downstream proteins in normal/benign luminal epithelial cells at the regular immunohistochemistry level. ..
  17. ncbi request reprint Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?
    Ping Tang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Diagn Mol Pathol 18:125-32. 2009
    ..We also propose a standardized IHC-based molecular classification, in the hope that it will promote more uniform large multicenter studies, and facilitate its clinical application...
  18. doi request reprint Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression
    Sanjib Banerjee
    Department of Surgery, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer Res 71:318-27. 2011
    ..Thus, our data demonstrate a novel immune escape and tumor growth-supporting mechanism mediated by soluble Hsp27 that may be operative in human breast cancer...
  19. doi request reprint Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Antonio C Wolff
    Antonio C Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore Lisa M McShane, National Cancer Institute, Bethesda, MD M Elizabeth H Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT David G Hicks, University of Rochester Medical Center, Rochester, NY Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom Kimberly H Allison, Stanford University Medical Center, Stanford Patrick Fitzgibbons, St Jude Medical Center, Fullerton Michael F Press, University of Southern California, Los Angeles, CA Donald C Allred, Washington University School of Medicine, St Louis, MO John M S Bartlett, Ontario Institute for Cancer Research Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia Robert B Jenkins, Mayo Clinic, Rochester, MN Pamela B Mangu, American Society of Clinical Oncology, Alexandria, VA Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, The Boston Consulting Group
    J Clin Oncol 31:3997-4013. 2013
    ....
  20. doi request reprint GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:2033-40. 2012
    ..Loss of GATA binding protein 3 was associated with high-grade and/or muscle-invasive tumors, whereas strong expression was an independent predictor of poor prognosis...
  21. ncbi request reprint The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course
    Brian J Yoder
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Clin Cancer Res 11:186-92. 2005
    ..If so, then fascin may represent a new molecular target for therapeutic intervention in patients with ER-negative breast cancer...
  22. ncbi request reprint A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution
    Joseph P Crowe
    Department of General Surgery Breast Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 80, Cleveland, OH 44195, USA
    Breast 15:728-35. 2006
    ..Correlates of HER2 amplification were higher Scarff-Bloom-Richardson grade, younger age at diagnosis, and a comedo ductal carcinoma in situ component...
  23. ncbi request reprint An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning
    Raymond R Tubbs
    Departments of Anatomical and Clinical Pathology, The Cleveland Clinic Foundation, The Lerner College of Medicine, Cleveland, OH 44195, USA
    J Mol Histol 38:141-50. 2007
    ....
  24. ncbi request reprint The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
    ..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...
  25. ncbi request reprint A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility
    William C Powell
    Ventana Medical Systems Inc, Tucson, AZ, USA
    Appl Immunohistochem Mol Morphol 15:94-102. 2007
    ..3% SI) in both cohorts. Interlaboratory reproducibility was also excellent (kappa 1.0). RMoAb 4B5 provides excellent sensitivity, specificity, and interlaboratory reproducibility for the detection of HER2 status in breast cancer...
  26. ncbi request reprint HER2 status in bilateral breast cancer
    Joseph P Crowe
    Departments of General Surgery Breast Center, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Int J Fertil Womens Med 51:219-23. 2006
    ..The purpose of this study was to identify correlates of HER2 status for patients with bilateral breast cancer...
  27. ncbi request reprint HER2-positive early breast cancer and trastuzumab: a surgeon's perspective
    Swati Kulkarni
    Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Ann Surg Oncol 15:1677-88. 2008
    ..If trastuzumab is approved for use in neoadjuvant regimens, the need for surgeons to be well informed about the appropriate use of this particular agent will become even more important...
  28. pmc Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients
    David G Hicks
    Department of Clinical and Anatomic Pathology, General Surgery Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 12:6702-8. 2006
    ....
  29. ncbi request reprint Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines
    David G Hicks
    Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:250-61. 2005
    ..The development of automated platforms for hybridization, image analysis for signal enumeration, and experience with FISH interpretation should broaden the availability of this technology for clinical diagnostic testing...
  30. ncbi request reprint The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
    Erinn Downs-Kelly
    Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am J Surg Pathol 29:1221-7. 2005
    ..These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma...
  31. pmc Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells
    Khalid Sossey-Alaoui
    Roswell Park Cancer Institute, Department of Cancer Genetics, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Am J Pathol 170:2112-21. 2007
    ..These studies provide direct evidence that the WAVE3-p38 pathway contributes to breast cancer progression and metastasis...
  32. ncbi request reprint Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study
    Raymond R Tubbs
    Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
    Appl Immunohistochem Mol Morphol 14:436-40. 2006
    ..Operational gains and enhanced consistency are inherent in this automated approach to HER2 clinical FISH testing...
  33. ncbi request reprint HER-2 testing in breast cancer
    Raymond R Tubbs
    JAMA 292:1817-8; author reply 1818. 2004
  34. doi request reprint The role of the indispensable surgical pathologist in treatment planning for breast cancer
    David G Hicks
    Arch Pathol Lab Med 132:1226-7. 2008
  35. ncbi request reprint The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
    David G Hicks
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 36:348-56. 2005
    ..If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy...
  36. ncbi request reprint The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer
    David G Hicks
    Arch Pathol Lab Med 129:1372-4. 2005
  37. ncbi request reprint High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallography
    Raymond Tubbs
    Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation, OH 44195, USA
    Appl Immunohistochem Mol Morphol 13:371-5. 2005
    ..This preliminary study shows the utility of using enzyme metallography for high-resolution immunophenotyping in TMAs...
  38. ncbi request reprint Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes
    Ken C Lo
    Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Genes Chromosomes Cancer 46:875-94. 2007
    ..This genome wide screen provides an efficient and comprehensive survey of genes which potentially serve as the drivers for the CNAs in GBM...
  39. ncbi request reprint Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience
    Raymond R Tubbs
    Anatomic and Clinical Pathology, Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
    Diagn Mol Pathol 16:207-10. 2007
    ..0 or more in at least 80% of tumor cells, was observed in 3% (20/742) of the cases. These data may be helpful as benchmarks for other institutions initiating primary FISH analysis for HER2 genotyping...
  40. ncbi request reprint Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR
    David G Hicks
    Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
    Am J Surg Pathol 30:1097-104. 2006
    ....
  41. pmc Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo
    Ali Ghadersohi
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA
    Breast Cancer Res Treat 102:19-30. 2007
    ..Furthermore, loss of PDEF expression in breast cancer tissues tends to be associated with unfavorable prognosis. These studies provide new information for the role of PDEF and survivin in breast cancer cell growth and tumor formation...
  42. ncbi request reprint Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    Brian Z Ring
    Applied Genomics Inc, 863 Mitten Rd 103, Burlingame, CA, USA
    J Clin Oncol 24:3039-47. 2006
    ..We have used gene expression data to guide the production of hundreds of novel antibody reagents to discover novel diagnostic tools for stratifying carcinoma patients...